Trial Profile
A Multi-Centre, Randomized, Double-Blind, Parallel Group, Active and Placebo Controlled, Proof of Concept Study in Patients With Acute Migraine to Assess the Efficacy, Safety and Tolerability of Single Oral Doses of BGG492.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Aug 2014
Price :
$35
*
At a glance
- Drugs Selurampanel (Primary) ; Sumatriptan
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 20 Aug 2013 Results published in the Cephalalgia.
- 31 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Aug 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.